Interestingly, a coding variant of RAPGEF3 that encodes EPAC1 and is positively correlated with body mass index, abolishes noradrenaline-induced proliferation of brown adipocytes. When activated, EPAC1 enhances the proliferation and differentiation of human brown adipocytes and human brown fat organoids. This protein coordinates a network of regulators specifically in thermogenic adipocytes but not in white adipocytes. Selective pharmacological activation of EPAC1 increases BAT mass and the browning of white fat. EPAC1: A Central Regulator of Adaptive BAT Growthįurther, EPAC1 has been identified as a central regulator of adaptive BAT (Brown Adipose Tissue) growth. The long-term goal is to find medicines that aid in weight loss.

This discovery is significant as it offers a new avenue for developing therapies that increase brown fat mass while simultaneously reducing white fat. The protein EPAC1, the researchers found, is responsible for the growth of brown fat and boosts the formation of brown fat cells in white fat. The study, published in the journal Nature Cell Biology, provides insights into the role of brown fat cells in converting energy into heat and protecting against cardiovascular diseases. The Role of EPAC1 in Brown Fat Mass and Activity They have identified the protein EPAC1 as a new pharmacological target that could aid in combating obesity and related metabolic diseases.

As researchers delve into the underlying mechanisms and potential treatments of these conditions, a team from the University Hospital Bonn and the University of Bonn’s Transdisciplinary Research Area ‘Life & Health’, have made a breakthrough discovery. In recent years, the global health community has seen a significant rise in obesity and related metabolic diseases.

Synergy wellness center facebook